Cloning and Expression of Domain III of Dengue Virus Type 2 Envelope Protein in Escherichia Coli

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Genetics, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran

2 Professor, Department of Genetics, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran

Abstract

Background: The aim of this study was production of a recombinant antigen from envelope protein of dengue virus, in order to achieve high level expression in soluble form. Therefore, the possibility of envelope protein domain III expression in bacterial host was studied.Methods: Multiple sequence alignment for domain III sequences was carried out using Megalign software. The Modeller and Optimizer software were used for protein structure prediction and sequence optimization. After gene synthesis and subcloning in the pET21a expression vector, the optimization of recombinant protein expression was carried out in Escherichia coli. Ni-NTA chromatography columns were used for protein purification. The efficiency of protein expression was analyzed using electrophoresis and western blotting methods.Findings: A consensus sequence for domain III of dengue virus type 2 envelope protein was provided. The structural properties of target protein were predicted using bioinformatics methods. For high expression level, the sequence of EDIII2 gene was optimized for appropriate codon usage and GC content. The coding gene sequence was approved by sequencing and enzymatic digestion. For disulfide bound formation in protein structure, the Origami (DE3) expression host was used. At the final step, expression of target protein was optimized, and a high concentration of recombinant protein was achieved in soluble form.Conclusion: The results of this study showed that the optimization of domain III sequence led to obtain high concentration (20 mg/l) of produced protein. This expression system can be used for production of dengue virus envelope protein domain III.

Keywords

References

  1. Leyssen P, de Clercq E, Neyts J. Perspectives for the treatment of infections with Flaviviridae. Clin Microbiol Rev 2000; 13(1): 67-82, table.
  2. Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv 2011; 29(2): 239-47.
  3. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18(Suppl 2): 44-7.
  4. Lai CJ, Bray M, Men R, Cahour A, Chen W, Kawano H, et al. Evaluation of molecular strategies to develop a live dengue vaccine. Clin Diagn Virol 1998; 10(2-3): 173-9.
  5. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001; 75(16): 7290-304.
  6. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174(6): 1176-84.
  7. Fonseca BA, Pincus S, Shope RE, Paoletti E, Mason PW. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 1994; 12(3): 279-85.
  8. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000; 18(27): 3113-22.
  9. Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009; 27(43): 6011-21.
  10. Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000; 18(27): 3166-73.
  11. Konishi E, Yamaoka M, Kurane I, Mason PW. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 2000; 18(11-12): 1133-9.
  12. Srivastava AK, Putnak JR, Warren RL, Hoke CH, Jr. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 1995; 13(13): 1251-8.
  13. Sugrue RJ, Cui T, Xu Q, Fu J, Chan YC. The production of recombinant dengue virus E protein using Escherichia coli and Pichia pastoris. J Virol Methods 1997; 69(1-2): 159-69.
  14. Simmons M, Nelson WM, Wu SJ, Hayes CG. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 1998; 58(5): 655-62.
  15. Hermida L, Rodriguez R, Lazo L, Lopez C, Marquez G, Paez R, et al. A recombinant envelope protein from Dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart. J Biotechnol 2002; 94(2): 213-6.
  16. Staropoli I, Clement JM, Frenkiel MP, Hofnung M, Deubel V. Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein. J Virol Methods 1996; 56(2): 179-89.
  17. Staropoli I, Frenkiel MP, Megret F, Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 1997; 15(17-18): 1946-54.
  18. Kelly EP, Greene JJ, King AD, Innis BL. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 2000; 18(23): 2549-59.
  19. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108(5): 717-25.
  20. Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 1992; 187(2): 480-91.
  21. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001; 75(16): 7769-73.
  22. Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. p. 91-1041.
  23. Chen Y, Maguire T, Marks RM. Demonstration of binding of dengue virus envelope protein to target cells. J Virol 1996; 70(12): 8765-72.
  24. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28(15): 2705-15.
  25. Izquierdo A, Bernardo L, Martin J, Santana E, Hermida L, Guillen G, et al. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 2008; 138(1-2): 135-8.
  26. Simmons M, Murphy GS, Hayes CG. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001; 65(2): 159-61.
  27. Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 2010; 28(51): 8085-94.
  28. Babu JP, Pattnaik P, Gupta N, Shrivastava A, Khan M, Rao PV. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 2008; 26(36): 4655-63.
  29. Volk DE, Lee YC, Li X, Thiviyanathan V, Gromowski GD, Li L, et al. Solution structure of the envelope protein domain III of dengue-4 virus. Virology 2007; 364(1): 147-54.
  30. Roehrig JT, Volpe KE, Squires J, Hunt AR, Davis BS, Chang GJ. Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol 2004; 78(5): 2648-52.
  31. Halstead SB, Heinz FX, Barrett AD, Roehrig JT. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine 2005; 23(7): 849-56.
  32. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York, NY: Cold Spring Harbor Laboratory Press; 1998.
  33. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227(5259): 680-5.
  34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
  35. Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res 2003; 59: 141-75.
  36. Puigbo P, Guzman E, Romeu A, Garcia-Vallve S. OPTIMIZER: a web server for optimizing the codon usage of DNA sequences. Nucleic Acids Res 2007; 35(Web Server issue): W126-W131.
  37. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003; 100(12): 6986-91.
  38. Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, Deubel V, et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 2001; 82(Pt 8): 1885-92.
  39. Fonseca BA, Khoshnood K, Shope RE, Mason PW. Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene. Am J Trop Med Hyg 1991; 44(5): 500-8.
  40. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004; 22(7): 346-53.
Journal of Isfahan Medical School
Volume 31, Issue 234 - Serial Number 234
March and April 2013
Pages 544-557

Files

History

  • Receive Date: 15 February 2013
  • Revise Date: 02 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics